Get started
Author

Man Kyu Shim

Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy
2018 · Man Kyu Shim, Jooho Park, et al. · Journal of Controlled Release · 172
Necroptosis‐Inducible Polymeric Nanobubbles for Enhanced Cancer Sonoimmunotherapy
2020 · Wooram Um, Hyewon Ko, et al. · Advanced Materials · 170
Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy
2021 · Jiwoong Choi, Man Kyu Shim, et al. · ACS Nano · 167
Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation
2022 · Hanhee Cho, Seong Ik Jeon, et al. · Pharmaceutics · 165
PDF
Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy
2019 · Seungho Lim, Jooho Park, et al. · Theranostics · 162
PDF
Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery
2022 · Man Kyu Shim, Suah Yang, et al. · Advanced Drug Delivery Reviews · 159
Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity
2021 · Suah Yang, Man Kyu Shim, et al. · Biomaterials · 147
Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
2022 · Yujeong Moon, Man Kyu Shim, et al. · Theranostics · 133
PDF
In Situ One-Step Fluorescence Labeling Strategy of Exosomes via Bioorthogonal Click Chemistry for Real-Time Exosome Tracking In Vitro and In Vivo
2020 · Sukyung Song, Man Kyu Shim, et al. · Bioconjugate Chemistry · 125
Cathepsin B‐Specific Metabolic Precursor for In Vivo Tumor‐Specific Fluorescence Imaging
2016 · Man Kyu Shim, Hong Yeol Yoon, et al. · Angewandte Chemie International Edition · 113
Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy
2020 · Man Kyu Shim, Yujeong Moon, et al. · Biomaterials · 111
Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer Immunotherapy
2024 · Yujeong Moon, Hanhee Cho, et al. · Angewandte Chemie International Edition · 95
Light‐Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy
2024 · Jiwoong Choi, Byeongmin Park, et al. · Advanced Materials · 78
PDF
Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance
2020 · Jinseong Kim, Man Kyu Shim, et al. · Journal of Controlled Release · 72
Effects of tumor microenvironments on targeted delivery of glycol chitosan nanoparticles
2017 · Ji Young Yhee, Sangmin Jeon, et al. · Journal of Controlled Release · 72
Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death
2020 · Yongwhan Choi, Hong Yeol Yoon, et al. · Pharmaceutics · 71
PDF
Caspase-3/-7-Specific Metabolic Precursor for Bioorthogonal Tracking of Tumor Apoptosis
2017 · Man Kyu Shim, Hong Yeol Yoon, et al. · Scientific Reports · 70
PDF
All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy
2023 · Sukyung Song, Man Kyu Shim, et al. · Bioactive Materials · 66
Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy
2019 · Wooram Um, Jooho Park, et al. · Biomaterials · 65
Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy
2025 · Byeongmin Park, Jiwoong Choi, et al. · Signal Transduction and Targeted Therapy · 62
PDF
In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy
2023 · Hanhee Cho, Seong Ik Jeon, et al. · Biomaterials · 62
Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity
2022 · Suah Yang, Man Kyu Shim, et al. · Biomaterials · 61
The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis
2021 · Jinseong Kim, Man Kyu Shim, et al. · Biomaterials · 60
Prediction the clinical EPR effect of nanoparticles in patient-derived xenograft models
2022 · Sangmin Jeon, Eunsung Jun, et al. · Journal of Controlled Release · 59
Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
2023 · Yujeong Moon, Seong Ik Jeon, et al. · Pharmaceutics · 58
PDF
Works count: 82
Citation count: 3,760
H-index: 37
I10-index: 64
Year
Topic
Type